Olympus said the US Food and Drug Administration has restricted imports of some products made at three of its facilities, but that it expects no additional effect on consolidated results for the year to March 2027 and is leaving its earlier forecast unchanged.
What the FDA did
On 19 October 2026, US time, the FDA published import alerts covering some products made at Olympus facilities. The named sites are Olympus Medical Systems (Hinode), Shirakawa Olympus and Aomori Olympus. Until further notice, the designated products are restricted from entering the US.
Olympus, whose president and CEO is Bob White, disclosed the alerts in a notice dated 21 October 2026. The notice does not list which products are covered or say how long the restriction could last beyond "until further notice".
What Olympus says it means
The company said it reviewed the alerts and does not expect them to add any impact on its consolidated results for the year to March 2027. The forecast it published earlier for that year is unchanged.
Olympus also said it does not expect significant effects on customers. Covered products already in customers' hands remain safe and effective, it said, as long as they are used according to the package inserts (instructions for use). It added that, at present, the alerts do not affect imports of the covered products into other countries.
The company said it puts patient safety first and will work transparently and constructively with the FDA to address the agency's findings. The notice does not describe those findings.
What to read next
The no-change statement is Olympus's own assessment, made within days of the FDA's publication. The notice gives no financial figure for the covered products, so the guidance claim rests on management's word. Earlier Tokyo Brief coverage is linked here: Earlier Tokyo Brief coverage.